Medpage Today on MSN8 个月
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management
Historically, myelofibrosis treatment was palliative in nature, aimed at relieving specific symptoms. The discovery of the ...
Nature8 年
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available ...
because BAT treatment would end with crossover to ruxolitinib as allowed per protocol. Consistent with previous reports and the mechanism of action of ruxolitinib as a potent JAK2 inhibitor ...
Cure Today9 天
Polycythemia Vera: Overview
A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red ...
The American Journal of Managed Care29 天
Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs
Finally, in an experiment with mouse model of mutated CALR-driven MPN, treatment with an antibody ... with most driven by mutations in Janus kinase (JAK2); this mutation accounts for 90% of ...